Poseida Therapeutics and Be The Match BioTherapies have partnered to deliver autologous chimeric antigen receptor T-cell therapies for multiple myeloma and prostate cancer. Poseida says it will launch a midstage trial for its multiple myeloma CAR T-cell therapy candidate P-BCMA-101 within the first half of 2019 and plans to submit an application for clinical development of its prostate cancer CAR T-cell treatment P-PSMA-101 with the FDA later in the year.
Collaboration will focus on providing cancer CAR T-cell therapies
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.